Page 141 - Read Online
P. 141

Page 14 of 15               Turati et al. Hepatoma Res 2022;8:19  https://dx.doi.org/10.20517/2394-5079.2021.130

               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2022.


               REFERENCES
               1.       Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future
                   perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev
                   Gastroenterol Hepatol 2016;13:261-80.  DOI  PubMed
               2.       Valle JW, Kelley RK, Nervi B, Oh D, Zhu AX. Biliary tract cancer. Lancet 2021;397:428-44.  DOI  PubMed
               3.       Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G, Heinemann V. Cholangiocarcinoma. Crit Rev Oncol Hematol
                   2009;69:259-70.  DOI  PubMed
               4.       Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011;54:173-84.  DOI  PubMed  PMC
               5.       Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014;383:2168-79.  DOI  PubMed  PMC
               6.       Wongjarupong  N,  Assavapongpaiboon  B,  Susantitaphong  P,  aet  al.  Non-alcoholic  fatty  liver  disease  as  a  risk  factor  for
                   cholangiocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2017;17:149.  DOI  PubMed  PMC
               7.       Choi J, Ghoz HM, Peeraphatdit T, et al. Aspirin use and the risk of cholangiocarcinoma. Hepatology 2016;64:785-96.  DOI  PubMed
                   PMC
               8.       Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev
                   Gastroenterol Hepatol 2020;17:557-88.  DOI  PubMed  PMC
               9.       Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115-25.  DOI  PubMed
               10.      Ellington TD, Momin B, Wilson RJ, et al. Incidence and mortality of cancers of the biliary tract, gallbladder, and liver by sex, age,
                   race/ethnicity, and stage at diagnosis: united states, 2013 to 2017. Cancer Epidemiol Biomarkers Prev 2021;30:1607-14.  DOI
                   PubMed
               11.      Gad MM, Saad AM, Faisaluddin M, et al. Epidemiology of cholangiocarcinoma; united states incidence and mortality trends. Clin Res
                   Hepatol Gastroenterol 2020;44:885-93.  DOI  PubMed
               12.      Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev
                   Clin Oncol 2018;15:95-111.  DOI  PubMed  PMC
               13.      Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin
                   tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006;98:873-5.  DOI
                   PubMed
               14.      Florio AA, Ferlay J, Znaor A, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012.
                   Cancer 2020;126:2666-78.  DOI  PubMed  PMC
               15.      Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the
                   rise. Oncologist 2016;21:594-9.  DOI  PubMed  PMC
               16.      Kim D, Konyn P, Cholankeril G, Bonham CA, Ahmed A. Trends in the mortality of biliary tract cancers based on their anatomical site
                   in the United States from 2009 to 2018. Am J Gastroenterol 2021;116:1053-62.  DOI  PubMed
               17.      Van Dyke AL, Shiels MS, Jones GS, et al. Biliary tract cancer incidence and trends in the United States by demographic group, 1999-
                   2013. Cancer 2019;125:1489-98.  DOI  PubMed  PMC
               18.      Patel N, Benipal B. Incidence of cholangiocarcinoma in the USA from 2001 to 2015: a us cancer statistics analysis of 50 states. Cureus
                   2019;11:e3962.  DOI  PubMed  PMC
               19.      Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol
                   2019;71:104-14.  DOI  PubMed
               20.      World Health Organization. WHO mortality database. Available from: https://www.who.int/data/data-collection-tools/who-mortality-
                   database [Last accessed on 2 Apr 2022].
               21.      World Health Organization. WHO mortality database. Available from: https://www.who.int/data/data-collection-tools/who-mortality-
                   database [Last accessed on 7 Apr 2022].
               22.      Pan American Health Organization (PAHO). Core indicators dashboard. Available from: https://opendata.paho.org/en/core-
                   indicators/core-indicators-dashboard [Last accessed on 7 Apr 2022].
               23.      Smith PG. Cancer Incidence in Five Continents. Comparison between registries: age-standardized rates. IARC Sci Publ ;1992:856-70.
                   PubMed
               24.      National Cancer Institute. Joinpoint trend analysis software. Available from: https://surveillance.cancer.gov/joinpoint/ [Last accessed
                   on 2 Apr 2022].
               25.      Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med
                   2000;19:335-51.  DOI  PubMed
               26.      Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a
   136   137   138   139   140   141   142   143   144   145   146